A Phase 3 interventional study of Docetaxel (TAXOTERE®) Chemotherapy and Leuprolide acetate ( ELIGARD®) Hormonal Therapy in Prostatic Neoplasms, sponsored by Sanofi. Completed at 17 sites in 17 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-26.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 30th largest by enrollment of the 185 interventional ones that give a count, is one of 21 that started in 2005, is one of 30 in phase 3, and was the 63rd registered.
7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+ · Men only
Charles Drew University of Medicine and Science · Sites in United States
Ages 18+ · Men only
Instituto do Cancer do Estado de São Paulo · Sites in Brazil
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 131 · Phase 3 34 · Phase 4 1
First in 1998; this study’s year is marked. 21 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 39 across the 185 interventional studies. Of the 143 that completed or were terminated, 53 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 193 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2005, is one of 10 in phase 3, and was the 7th registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
6 of the studies testing docetaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT06480110Rigshospitalet, DenmarkEbastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | 2026-12-01 |
| NCT04633252National Cancer Institute (NCI)A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | 2026-12-31 |
| NCT04015622British Columbia Cancer AgencyPROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | 2027-01-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, open-label, randomized phase III study in participants at high risk of recurrent prostate cancer after radical prostatectomy. The study will investigate
Using a 2x2 factorial design participants will therefore be randomized to
Primary Objective:
Secondary Objectives:
Originally, 1696 participants were planned in the study (with 424 participants randomized to each arm). However, only a total of 211 participants completed the randomization procedure as of 26 September 2007. Thus, sanofi-aventis, in accordance with the Steering Committee, decided to stop the participant recruitment as of 26 September 2007. Participants who had already signed their Informed Consent (IC) before September 26, 2007 were allowed to enter the randomization if they met eligibility criteria. The final revised number of planned participants to be randomly assigned to the 4 treatment arms was 250, and 228 participants were actually randomized.
The final sample size did not allow all the statistical analyses to be conducted on efficacy data. Therefore, the protocol was amended to reflect the change in the plans for statistical analysis. The study was underpowered to serve as the basis for drawing conclusions regarding efficacy and quality of life (QoL) endpoints.
The study consisted of the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who met all of the following criteria were considered for enrollment into the study.
Hematology evaluation within 2 weeks prior to randomization:
Hepatic and renal function evaluation within 2 weeks prior to randomization:
Exclusion Criteria:
Participants presenting with any of the following will not be included in the study.
Participants taking alternative therapies for cancer must stop taking these therapies prior to randomization. Alternative therapies are not allowed during the treatment or follow-up portions of the study. This includes (but is not limited to) alternative therapies such as :
History of a other than prostate cancer. Exceptions to these criteria include:
The above information was not intended to contain all considerations relevant to potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
Drug: Docetaxel (TAXOTERE®) Chemotherapy · Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
Drug: Docetaxel (TAXOTERE®) Chemotherapy · Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization. Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed. Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression
PFS is the interval from the date of surgery to date of progression. The date of progression was the earlier of * first PSA increase to ≥ 0.4 ng/mL confirmed within two weeks * date of the nadir, if PSA nadir did not reach \< 0.4 ng/mL (for deferred arm) * first radiological/ histological evidence of tumor progression * death. Median PFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Median PFS could not be estimated. Reported is the number of participants with disease progression.
Time frame: from the date of surgery up to 3 years after randomization of the last participant
Median Overall Survival (OS)
Overall survival (OS) was the time interval from the date of surgery to the date of death due to any cause. Median OS was to be estimated using Kaplan-Meier Curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Moreover, median OS could not be estimated. Reported is the number of participants who died from any cause.
Time frame: from the date of surgery up to 3 years after randomization of the last participant
Median Cancer-specific Survival (CSS)
The CSS was the time from the date of surgery to the date of death due to prostate cancer. Median CSS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median CSS was not estimated.
Time frame: from the date of surgery up to 3 years after randomization of the last participant
Median Metastasis-free Survival (MFS)
MFS was the interval from the date of surgery to the date of the first clinical evidence of metastasis after treatment initiation. Metastasis was evaluated by a physical exam or radiologically on bone scan or CT scan. Local (palpable) progression, documented histologically or by imaging techniques was considered evidence of progression. Median MFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median MFS was not estimated.
Time frame: from the date of surgery up to 3 years after randomization of the last participant
To Evaluate Quality of Life (QoL) as Measured Using a Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire
The FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better QoL with fewer symptoms. A score of 156 represents the best outcome. Note: Enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn due to the low sample size.
Time frame: from 30 days before randomization (baseline) and 18 months after treatment initiation (for change from baseline)
Assessment of Safety and Tolerability - Number of Participants With Adverse Events (AE)
Number of participants with treatment-emergent adverse events (TEAE). A TEAE was as any adverse event that occurred or worsened during the on-treatment period, which was the period from the day of first infusion of study treatment until 30 days after the last infusion of study treatment.
Time frame: from treatment initiation up to 19 months after treatment initiation
Originally, the study was planned for 1696 participants to be randomized. However, enrollment was not met and in September 2007, the Steering Committee decided to stop recruitment. Only participants who had signed Informed Consent by then and met eligibility criteria were randomized. 228 participants were randomized to this study.
| Milestone | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| Started | 55 | 55 | 56 | 62 |
| Administered study treatment | 50 | 51 | 20 | 17 |
| Completed hormonal therapy (6 cycles) | 44 | 48 | 15 | 13 |
| Completed chemotherapy (6 cycles) | 43 | 0 | 15 | 0 |
| Completed | 43 | 48 | 15 | 13 |
| Not completed | 12 | 7 | 41 | 49 |
| Withdrew: Did not receive any study medication | 5 | 4 | 36 | 45 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 |
| Withdrew: Participant did not wish to continue | 3 | 2 | 1 | 0 |
| Withdrew: Undefined | 0 | 1 | 1 | 4 |
| Withdrew: Chemotherapy not completed (cycle 6) | 1 | 0 | 0 | 0 |
PFS is the interval from the date of surgery to date of progression. The date of progression was the earlier of * first PSA increase to ≥ 0.4 ng/mL confirmed within two weeks * date of the nadir, if PSA nadir did not reach \< 0.4 ng/mL (for deferred arm) * first radiological/ histological evidence of tumor progression * death. Median PFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Median PFS could not be estimated. Reported is the number of participants with disease progression.
| participants | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression | 10 | 14 | 9 | 8 |
Overall survival (OS) was the time interval from the date of surgery to the date of death due to any cause. Median OS was to be estimated using Kaplan-Meier Curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Moreover, median OS could not be estimated. Reported is the number of participants who died from any cause.
| participants | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| Median Overall Survival (OS) | 0 | 2 | 1 | 1 |
The CSS was the time from the date of surgery to the date of death due to prostate cancer. Median CSS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median CSS was not estimated.
No measurements were reported for this outcome.
MFS was the interval from the date of surgery to the date of the first clinical evidence of metastasis after treatment initiation. Metastasis was evaluated by a physical exam or radiologically on bone scan or CT scan. Local (palpable) progression, documented histologically or by imaging techniques was considered evidence of progression. Median MFS was to be estimated using Kaplan-Meier curves. However, enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn. Therefore, based on a protocol amendment, median MFS was not estimated.
No measurements were reported for this outcome.
The FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better QoL with fewer symptoms. A score of 156 represents the best outcome. Note: Enrollment was not met, and meaningful conclusions for efficacy or QoL could not be drawn due to the low sample size.
| score on a scale | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| Baseline | 124.0 ± 6.0 | 121.5 ± 17.8 | 114.7 ± 13.9 | 119.7 ± 15.8 |
| Change from Baseline (N=33, N=41, N=12, N=10) | 0.7 ± 12.6 | 1.7 ± 17.2 | 6.7 ± 15.9 | 6.1 ± 18.9 |
Number of participants with treatment-emergent adverse events (TEAE). A TEAE was as any adverse event that occurred or worsened during the on-treatment period, which was the period from the day of first infusion of study treatment until 30 days after the last infusion of study treatment.
| participants | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| with any adverse event (AE) | 47 | 48 | 19 | 14 |
| with any serious adverse event (SAE) | 12 | 8 | 5 | 2 |
| with an SAE resulting in death | 0 | 0 | 0 | 0 |
| with a drug-related AE | 47 | 43 | 18 | 10 |
| with a drug-related SAE | 6 | 0 | 2 | 0 |
| with AE leading to discontinue all study therapy | 2 | 0 | 1 | 0 |
| with AE leading to chemotherapy discontinuation | 1 | NA | 1 | NA |
| with AE leading to chemotherapy dose reduction | 5 | NA | 2 | NA |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | — | 12/50 (24%) | 47/50 (94%) |
| Leuprolide Acetate - Immediate Treatment (I-HT) | — | 8/51 (15.7%) | 48/51 (94.1%) |
| Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | — | 5/20 (25%) | 19/20 (95%) |
| Leuprolide Acetate - Deferred Treatment (D-HT) | — | 2/17 (11.8%) | 13/17 (76.5%) |
| Event | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/50 | 0/51 | 2/20 | 0/17 |
| ArthropathyMusculoskeletal and connective tissue disorders | 1/50 | 0/51 | 0/20 | 1/17 |
| Blood cholesterol increasedInvestigations | 0/50 | 0/51 | 0/20 | 1/17 |
| Blood glucose increasedInvestigations | 0/50 | 0/51 | 0/20 | 1/17 |
| Blood triglycerides increasedInvestigations | 0/50 | 0/51 | 0/20 | 1/17 |
| ColitisGastrointestinal disorders | 0/50 | 0/51 | 1/20 | 0/17 |
| DiarrhoeaGastrointestinal disorders | 0/50 | 0/51 | 1/20 | 0/17 |
| PyrexiaGeneral disorders | 1/50 | 0/51 | 1/20 | 0/17 |
| FatigueGeneral disorders | 0/50 | 0/51 | 1/20 | 0/17 |
| Oedema peripheralGeneral disorders | 0/50 | 0/51 | 1/20 | 0/17 |
| Event | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) |
|---|---|---|---|---|
| Hot flushVascular disorders | 36/50 | 38/51 | 11/20 | 8/17 |
| FatigueGeneral disorders | 32/50 | 16/51 | 13/20 | 3/17 |
| AlopeciaSkin and subcutaneous tissue disorders | 29/50 | 0/51 | 9/20 | 0/17 |
| DysgeusiaNervous system disorders | 17/50 | 0/51 | 5/20 | 0/17 |
| Erectile dysfunctionReproductive system and breast disorders | 15/50 | 17/51 | 1/20 | 1/17 |
| NauseaGastrointestinal disorders | 16/50 | 4/51 | 4/20 | 1/17 |
| DiarrhoeaGastrointestinal disorders | 14/50 | 2/51 | 6/20 | 0/17 |
| Nail disorderSkin and subcutaneous tissue disorders | 14/50 | 0/51 | 6/20 | 0/17 |
| Urinary incontinenceRenal and urinary disorders | 15/50 | 14/51 | 0/20 | 2/17 |
| HeadacheNervous system disorders | 14/50 | 3/51 | 3/20 | 0/17 |
| Age Continuous(years) | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) | Total |
|---|---|---|---|---|---|
| Mean | 61.2 ± 7.4 | 61.6 ± 7.0 | 62.1 ± 7 | 62.9 ± 7.5 | 61.9 ± 7.2 |
| Age, Customized(participants) | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) | Total |
|---|---|---|---|---|---|
| <65 years | 37 | 34 | 35 | 35 | 141 |
| >=65 years | 18 | 21 | 21 | 27 | 87 |
| Sex: Female, Male(Participants) | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 55 | 55 | 56 | 62 | 228 |
| Race/Ethnicity, Customized(participants) | Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT) | Leuprolide Acetate - Immediate Treatment (I-HT) | Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT) | Leuprolide Acetate - Deferred Treatment (D-HT) | Total |
|---|---|---|---|---|---|
| White | 48 | 49 | 43 | 59 | 199 |
| Black | 6 | 3 | 7 | 2 | 18 |
| Asian/Oriental | 0 | 1 | 4 | 0 | 5 |
| Multiracial | 0 | 0 | 2 | 0 | 2 |
| Other | 1 | 2 | 0 | 1 | 4 |
The record gives a start of Dec 2005, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel